Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.56 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.40 |
| ▸ | LPL | P06858 | 7/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31294840 | 0.98 | DGAT1 (0.56) | DGAT1LIPGLPLRENHRH4 | |
| SCHEMBL2067941 | 0.94 | DGAT1 (0.57) | DGAT1LIPGLPLKEAP1NFE2L2 | |
| SCHEMBL20120561 | 0.93 | DGAT1 (0.56) | DGAT1LIPGLPLKEAP1NFE2L2 | |
| SCHEMBL1180731 | 0.87 | DGAT1 (0.66) | DGAT1LIPGLPLFFAR1 | |
| SCHEMBL29986429 | 0.87 | DGAT1 (0.66) | DGAT1LIPGLPLFFAR1 | |
| SCHEMBL19794893 | 0.81 | DGAT1 (0.53) | DGAT1LIPGLPLFFAR1 | |
| SCHEMBL21327400 | 0.81 | DGAT1 (0.57) | DGAT1LIPGLPLFFAR1 | |
| SCHEMBL20294856 | 0.81 | DGAT1 (0.55) | DGAT1LIPGLPLTDP1L3MBTL1 | |
| SCHEMBL10224532 | 0.79 | DGAT1 (0.55) | DGAT1LIPGLPL | |
| SCHEMBL17072107 | 0.79 | DGAT1 (0.43) | DGAT1LIPGLPLKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | DGAT1 989/4885LIPG 398/4885LPL 739/4885 |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | DGAT1 989/4885LIPG 398/4885LPL 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.